Brandon Couillard

The 6% growth in China, was that all stimulus related and would be helpful if you can just touch on a couple of the end markets there.

I think Simon said Europe was pretty solid. So just curious where you're seeing the weakness visits all in the Americas?

Do you expect to see a halo benefit as the instrument cycle continues to escalate next year? Or are you just sort of being conservative here

What was net pricing in the fourth quarter? And I think you talked about 100 basis points in fiscal '26, but that there could be upside to that.

Bob, you took down the operating cash flow guide for the year. Is that driven by tariffs and maybe inventory builds?

Are you less likely to consider a larger deal right now given the macro, tariffs, interest rate volatility? Or are you seeing more attractive valuations for assets?

it'd be great if you could get an update just on the pathology and genomics pieces and how those performed in the first quarter.

Bob, can you just help us understand what's going on with gross margins, down over 130 basis points in the first quarter? Was that in line with your expectations?

how much of the CapEx is in Nexter is tied to the train B and build out for NASD, we expect those to come online, and what does maintenance CapEx look like?

can you remind us, you know, when the Infinity 2 I think it's the 1290 system rolled out. And what's the is there an ASP premium?

Are there any pockets of lab that are doing better, like bioprocess there

it's atypical for Mettler to do one deal, much less a handful of them. I'd love if you could just kind of elaborate on how this came about

did you give the lab -- the China lab growth in the quarter? And what is embedded for '25 for China and those 2 segments specifically

When you're talking about seeing some orders being delayed, some pushouts for projects, is that isolated to core industrial? Was that a China-specific comment or more global

it doesn't look like your free cash flow guide actually changed at all. How do you just, I guess, approach managing working capital in this environment

can you give us a little more color on the levers to improvement there and kind of where you're seeing free cash flow shake out for '26?

You're sticking with the 100 basis points for the full year. But you previously talked about maybe exiting up 200 bps year-over-year

question on operating cash flow down pretty meaningfully. In the first half

How would that kind of break down between consumables and instruments? And was there any stimulus benefit in the period?

Does that assume an accelerating top line outlook? And if you could just touch on kind of what's embedded for net pricing and any tariff headwinds

second quarter in a row, China has been up double digits, a lot better than peers. Do you think that's unique to Waters in your portfolio

Did the PFAS business thing to really accelerate quite a bit here in the quarter, clocking a new high up 90%. Is there any timing benefit in that growth rate

What's your appetite for another $1 billion-plus deal or maybe even something more transformative

your PFAS market sizing continues to walk up. Now, you're talking about a $400 million opportunity, prior it was kind of $300 million to $350 million

I think you talked about instrument growth this year 4%, 4.5%. Just curious how that compares between the LC, mass spec and light scattering